Guo, Zong Sheng and Lotze, Michael T. and Zhu, Zhi and Storkus, Walter J. and Song, Xiao-Tong
(2020)
Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy.
Biomedicines, 8 (7).
p. 204.
ISSN 2227-9059
Abstract
Oncolytic viruses (OVs) are potent anti-cancer biologics with a bright future, having substantial evidence of efficacy in patients with cancer. Bi- and tri-specific antibodies targeting tumor antigens and capable of activating T cell receptor signaling have also shown great promise in cancer immunotherapy. In a cutting-edge strategy, investigators have incorporated the two independent anti-cancer modalities, transforming them into bi- or tri-specific T cell engager (BiTE or TriTE)-armed OVs for targeted immunotherapy. Since 2014, multiple research teams have studied this combinatorial strategy, and it showed substantial efficacy in various tumor models. Here, we first provide a brief overview of the current status of oncolytic virotherapy and the use of multi-specific antibodies for cancer immunotherapy. We then summarize progress on BiTE and TriTE antibodies as a novel class of cancer therapeutics in preclinical and clinical studies, followed by a discussion of BiTE- or TriTE-armed OVs for cancer therapy in translational models. In addition, T cell receptor mimics (TCRm) have been developed into BiTEs and are expected to greatly expand the application of BiTEs and BiTE-armed OVs for the effective targeting of intracellular tumor antigens. Future applications of such innovative combination strategies are emerging as precision cancer immunotherapies.
Share
| Citation/Export: |
|
| Social Networking: |
|
Details
| Item Type: |
Article
|
| Status: |
Published |
| Creators/Authors: |
|
| Centers: |
Other Centers, Institutes, Offices, or Units > Hillman Cancer Center |
| Date: |
10 July 2020 |
| Date Type: |
Publication |
| Journal or Publication Title: |
Biomedicines |
| Volume: |
8 |
| Number: |
7 |
| Publisher: |
MDPI AG |
| Page Range: |
p. 204 |
| DOI or Unique Handle: |
10.3390/biomedicines8070204 |
| Schools and Programs: |
School of Medicine > Surgery |
| Refereed: |
Yes |
| Uncontrolled Keywords: |
oncolytic virus, bispecific antibody, trispecific antibody, bispecific T cell engager, trispecific T cell engager, tumor antigen-specific T cells |
| ISSN: |
2227-9059 |
| Official URL: |
http://dx.doi.org/10.3390/biomedicines8070204 |
| Funders: |
UPMC Immune Transplant and Therapy Center, U.S. Department of Defense, Congressionally Directed Medical Research Programs |
| Article Type: |
Review |
| Date Deposited: |
25 May 2021 19:40 |
| Last Modified: |
25 May 2021 19:40 |
| URI: |
http://d-scholarship.pitt.edu/id/eprint/41153 |
Metrics
Monthly Views for the past 3 years
Plum Analytics
Altmetric.com
Actions (login required)
 |
View Item |
![[feed]](/images/feed-icon-32x32.png){kind=icon}